Market Intelligence

Current PBM Model Threatened by New-Entity PBMs

Posted on by aprilgregory

Changes are happening in the PBM market. Traditional services offered by PBMs will be supplanted by new PBM entities that will develop formularies among the services they offer. The new entity PBMs manage and supplement PBM services as an advocate for health care payers. Services include prescription claims analysis and consultation, drug coverage management, PBM contracts […]

Continue reading →
Dr. Randy Vogenberg, Market Intelligence

Biosimilar Confusion and Insights

Posted on by Dr. Randy

Since Virginia became the first state in May 2013 to enact legislation regulating a pharmacist’s substitution of an interchangeable biologic drug for a prescribed reference biologic drug, there has not been much activity or clarity on the issue. This issue continues to pit manufacturer versus manufacturer, and other stakeholders against each other in the policy […]

Continue reading →
Market Intelligence

More problems for the public over ObamaCare

Posted on by Dr. Randy

More problems for the public over ObamaCare come home to roost at tax time unlike commercial insured The following information was released by the Tax Foundation: According to the tax preparation firm, HandR Block, as many as 3.4 million people, or half of all who received subsidies for health insurance through Obamacare exchanges, will have […]

Continue reading →
Uncategorized

John Santilli quoted in Modern Medicine: Ebola clinical activity heats up with vaccine candidates in works

Posted on by John Santilli

Ebola is unlikely to become a profitable endeavor for Western pharmaceutical companies, “affecting primarily the poor in Africa with demand for drugs relatively modest,” according to John Santilli, of Access Market Intelligence, which provides market intelligence to the pharmaceutical and healthcare industries. http://formularyjournal.modernmedicine.com/formulary-journal/news/ebola-clinical-activity-speeds-vaccine-candidates-works

Continue reading →
Uncategorized

John Santilli quoted in Modern Medicine: Top Five Industry Challenges of 2015

Posted on by John Santilli

Employers and insurers are responding to costs of expensive drugs like Sovaldi with step therapy, or higher tiers of drug-payment categories, and shifting the site of care from hospitals to physician offices, says John Santilli, partner in Access Market Intelligence. Read more here: http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/top-five-industry-challenges-2015?page=0,7

Continue reading →
Uncategorized

John Santilli quoted in Modern Medicine: Olysio indication expanded for combo use with Sovaldi in hepatitis C

Posted on by John Santilli

“[Hepatitis C] is a very competitive market, as a number of companies are looking to compete with Gilead’s products due to the large population of patients and the high earnings potential for drug sales,” said John Santilli, of Access Market Intelligence, which provides market intelligence to the pharmaceutical and healthcare industries.  Read more here: http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/top-five-industry-challenges-2015?page=0,7

Continue reading →
Uncategorized

John Santilli quoted in Modern Medicine: FDA warns of rare brain infection with MS drug Tecfidera

Posted on by John Santilli

New oral therapies Biogen Idec’s dimethyl fumarate is one of the new market entrants driving the shift to oral therapy growth in MS treatment, according to John Santilli of Access Market Intelligence, which provides business information to the pharmaceutical and healthcare industries. “Although this is Tecfidera’s first incident tied to PML use in more than 100,000 […]

Continue reading →